- TitleChairman and CEO
After growing Allergan from a small eye care outfit to a pharmaceutical superstar, CEO David Pyott is in the fight of his career. A $55 billion hostile takeover bid from Canada-based competitor Valeant and hedge fund manager Bill Ackman has turned into an ugly battle. A recent overture from a potential white knight may save the Botox maker from Valeant’s advances after all. Pyott and Allergan have kept up the fight and continue to post strong results. The firm’s earnings for the third quarter of 2014 surpassed analyst expectations and sales grew by 17% compared to the previous year. During his 16 years at the helm, Pyott has increased the company’s market cap by $50 billion to a healthy $58 billion, a stellar performance that has put him at the top of the heap among CEOs worldwide. —J.A.